Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Dow
Express Scripts
AstraZeneca
Mallinckrodt

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

Claims for Patent: 7,824,907

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,824,907
Title:Expression vectors comprising the mCMV IE2 promoter
Abstract: The invention relates to an expression vector comprising the promoter of the mCMV-IE2 gene, or a functional expression promoting fragment thereof, and/or an enhancer of the mCMV-IE2 gene, or a functional expression enhancing fragment thereof, wherein expression vector does not contain any complete gene of the mCMV.
Inventor(s): Chatellard; Philippe (Lausanne, CH), Imhof; Markus (Chexbres, CH)
Assignee: Merck Serono SA (Coinsins, Vaud, CH)
Application Number:10/548,364
Patent Claims:1. An expression vector comprising SEQ ID NO: 1, wherein: (i) SEQ ID NO: 1 comprises a murine cytomegalovirus intermediate early 2 (mCMV-IE2) promoter; (ii) the expression vector does not contain any complete gene of the murine cytomegalovirus (mCMV); and (iii) said mCMV-IE2 promoter is operably linked to a DNA sequence coding for a polypeptide.

2. The vector according to claim 1, said vector comprising a first promoter comprising said mCMV-IE2 promoter and a second promoter that is different from said mCMV-IE2 promoter.

3. The vector according to claim 2, wherein the first and the second promoters are operably linked to DNA sequences coding for at least one polypeptide.

4. The vector according to claim 3, wherein the DNA sequences code for at least one protein of interest.

5. The vector according to claim 3, wherein the DNA sequences code for at least one marker protein.

6. The vector according to claim 3, wherein the DNA sequences code for at least one reporter protein.

7. The vector according to claim 2, wherein the first promoter and the second promoter are hi-directionally arranged.

8. The vector according to claim 2, further comprising one or more regulatory elements selected from the group consisting of 5'UTRs, introns, 3'UTRs, mRNA 3' end processing sequences, polyadenylation sites, and internal ribosome entry sequences (IRES).

9. The vector according to claim 8, wherein the regulatory element is an IRES, further comprising a DNA sequence coding for at least one polycistronic mRNA.

10. The vector according to claim 8, further comprising one or more DNA elements selected from the group consisting of insulators, boundary elements, locus control regions (LCRs), matrix attachment regions (MARs), and elements for recombination and cassette exchange.

11. The vector according to claim 3, wherein the DNA sequence coding for the polypeptide operably linked to the first promoter and the DNA sequence coding for the polypeptide operably linked to the second promoter code for the same polypeptide.

12. The vector according to claim 3, wherein the DNA sequence coding for the polypeptide operably linked to the first promoter and the DNA sequence coding for the polypeptide operably linked to the second promoter code for different polypeptides.

13. The vector according to claim 12, wherein the DNA sequence coding for the polypeptide operably linked to the first promoter codes for a first subunit of a dimeric or multimeric protein and the DNA sequence coding for the polypeptide operably linked to the second promoter codes for a second subunit of a dimeric or multimeric protein.

14. The vector according to claim 13, wherein one subunit is the alpha chain and the other subunit is the beta chain of a hormone selected from human follicle stimulating hormone (FSH), human leutropin-choriogonadotropic hormone (LH), human thyroid stimulating hormone (TSH), and human chorionic gonadotropin hormone (CG).

15. The vector according to claim 12, wherein one subunit is the heavy chain and the other subunit is the light chain of an immunoglobulin.

16. The vector according to claim 4, wherein the protein of interest is selected from the group consisting of follicle stimulating hormone (FSH), leutropin-choriogonadotropic hormone (LH), chorionic gonadotropin (CG), thyroid stimulating hormone (TSH), growth hormone, interferon, tumor necrosis factor (TNF) binding protein I, TNF binding protein II, a humanized anti-CD11 antibody, interleukin-18 binding protein (IL-18BP) and fusion proteins thereof.

17. The vector according to claim 5, wherein the marker protein is selected from the group consisting of adenosine deaminase (ADA), aminoglycoside phosphotransferase (neo), dihydrofolate reductase (DHFR), hygromycin-B-phosphotransferase (HPH), thymidine kinase (tk), xanthine-guanine phosphoribosyltransferase (gpt), multiple drug resistance gene (MDR), ornithine decarboxylase (ODC) and N-(phosphonacetyl)-L-aspartate resistance (CAD), puromycin acetyltransferase (PAC), galactokinase, human folate receptor, and reduced folate carriers.

18. The vector according to claim 6, wherein the reporter protein is selected from the group consisting of luciferase, green fluorescent protein, alkaline phosphates, and horseradish peroxidase and combinations thereof.

19. The expression vector according to claim 1, wherein said mCMV-IE2 promoter is operably linked to a DNA sequence coding for a polypeptide selected from the group consisting of follicle stimulating hormone (FSH), leutropin-choriogonadotropic hormone(LH), chorionic gonadotropin (CG), thyroid stimulating hormone (TSH), growth hormone, interferon, tumor necrosis factor (TNF) binding protein I, TNF binding protein II, a humanized anti-CD11 antibody, interleukin-18 binding protein (IL-18BP), and fusion proteins thereof.

20. A host cell transfected with a vector according to claim 1.

21. The host cell according to claim 20, wherein the host cell is a CHO cell.

22. A process for the production of a polypeptide comprising culturing a host cell according to claim 20 under conditions allowing expression of the polypeptide.

23. The process according to claim 22, wherein the host cell is stably transfected.

24. The process according to claim 22, further comprising the step of isolating the polypeptide from the host cell or cell culture supernatant.

25. The process according to claim 22, further comprising the step of isolating the polypeptide from the host cell or cell culture supernatant.

26. The vector according to claim 16, wherein the protein of interest is IL-18BP or fusion proteins thereof.

27. The process according to claim 22, wherein said polypeptide is IL-18BP or fusion proteins thereof.

28. The expression vector according to claim 1, wherein said polypeptide is selected from the group consisting of interferon beta-1a, interferon beta-1b, an interferon receptor, an interleukin, erythropoietin, granulocyte colony stimulating factor, granulocyte-macrophage colony-stimulating factor, a pituitary peptide hormone, menopausal gonadotropin, an insulin-like growth factor, keratinocyte growth factor, glial cell line-derived neurotrophic factor, thrombomodulin, basic fibroblast growth factor, insulin, Factor VIII, somatropin, bone morphogenetic protein-2, platelet-derived growth factor, hirudin, epoietin, a recombinant LFA-3/IgG1 fusion protein, glucocerebrosidase and fusion proteins thereof.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
03100617Mar 11, 2003
PCT Information
PCT FiledMarch 10, 2004PCT Application Number:PCT/EP2004/050280
PCT Publication Date:September 23, 2004PCT Publication Number:WO2004/081167

Details for Patent 7,824,907

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bayer Healthcare Pharms BETASERON interferon beta-1b VIAL; SUBCUTANEOUS 103471 001 1993-07-23   Start Trial Merck Serono SA (Coinsins, Vaud, CH) 2023-03-11 RX Orphan search
Biogen AVONEX interferon beta-1a VIAL 103628 001 1996-05-17   Start Trial Merck Serono SA (Coinsins, Vaud, CH) 2023-03-11 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 001 2002-03-07   Start Trial Merck Serono SA (Coinsins, Vaud, CH) 2023-03-11 RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 002 2002-03-07   Start Trial Merck Serono SA (Coinsins, Vaud, CH) 2023-03-11 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Mallinckrodt
Colorcon
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.